Exelixis (EXEL) Competitors $39.63 -0.38 (-0.95%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$39.50 -0.13 (-0.33%) As of 10/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL vs. BIIB, UTHR, INCY, NBIX, BMRN, IONS, EXAS, MDGL, HALO, and RGENShould you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exelixis vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Ionis Pharmaceuticals Exact Sciences Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Which has preferable valuation and earnings, BIIB or EXEL? Biogen has higher revenue and earnings than Exelixis. Biogen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.31$1.63B$10.4614.55Exelixis$2.17B4.92$521.27M$2.0819.05 Is BIIB or EXEL more profitable? Exelixis has a net margin of 27.01% compared to Biogen's net margin of 15.31%. Exelixis' return on equity of 27.47% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Exelixis 27.01%27.47%20.88% Does the media refer more to BIIB or EXEL? In the previous week, Biogen had 6 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for Biogen and 11 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Biogen's score of 0.97 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 9 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in BIIB or EXEL? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, BIIB or EXEL? Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Do analysts recommend BIIB or EXEL? Biogen currently has a consensus price target of $180.04, indicating a potential upside of 18.28%. Exelixis has a consensus price target of $44.42, indicating a potential upside of 12.09%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 1 Sell rating(s) 20 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.31Exelixis 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.63 SummaryExelixis beats Biogen on 10 of the 16 factors compared between the two stocks. Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXEL vs. The Competition Export to ExcelMetricExelixisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.77B$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.69%4.74%P/E Ratio19.0521.4185.6126.85Price / Sales4.92466.25612.81135.13Price / Cash20.7747.6737.7861.77Price / Book5.0410.0613.256.70Net Income$521.27M-$52.22M$3.30B$276.44M7 Day Performance-3.81%4.25%3.87%2.48%1 Month Performance5.15%12.50%8.33%8.79%1 Year Performance56.09%26.68%88.97%34.41% Exelixis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXELExelixis4.8289 of 5 stars$39.63-0.9%$44.42+12.1%+50.6%$10.77B$2.17B19.051,147Positive NewsBIIBBiogen4.5652 of 5 stars$139.28+0.6%$182.04+30.7%-17.0%$20.38B$9.68B13.297,605Analyst ForecastUTHRUnited Therapeutics4.3203 of 5 stars$422.85-0.3%$449.57+6.3%+30.6%$19.11B$2.88B16.531,305Insider TradeINCYIncyte4.5088 of 5 stars$84.62+0.9%$83.67-1.1%+32.6%$16.51B$4.24B19.212,617NBIXNeurocrine Biosciences4.7811 of 5 stars$139.86-0.3%$161.89+15.8%+22.1%$13.87B$2.51B41.361,800News CoverageBMRNBioMarin Pharmaceutical4.9513 of 5 stars$53.85-0.3%$92.60+72.0%-20.7%$10.33B$2.85B15.963,040IONSIonis Pharmaceuticals3.409 of 5 stars$64.87+1.1%$73.88+13.9%+82.1%$10.32B$944.05M-35.181,069Analyst ForecastEXASExact Sciences4.5021 of 5 stars$53.85+0.9%$68.05+26.4%-16.6%$10.21B$2.76B-9.937,000Analyst ForecastMDGLMadrigal Pharmaceuticals4.309 of 5 stars$450.11+1.6%$495.88+10.2%+103.1%$10.03B$180.13M-35.1490HALOHalozyme Therapeutics4.6736 of 5 stars$73.77+0.7%$69.89-5.3%+22.6%$8.63B$1.02B16.88390Analyst RevisionRGENRepligen4.6142 of 5 stars$130.88+5.5%$168.75+28.9%+6.8%$7.36B$673.96M-523.481,778Analyst Forecast Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Ionis Pharmaceuticals Alternatives Exact Sciences Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXEL) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
